Invention Grant
- Patent Title: Fc-epsilon car
-
Application No.: US17341098Application Date: 2021-06-07
-
Publication No.: US11643452B2Publication Date: 2023-05-09
- Inventor: Laurent H. Boissel , Hans G. Klingemann , Abhijit Dandapat , Himani Chinnapen
- Applicant: ImmunityBio, Inc.
- Applicant Address: US CA El Segundo
- Assignee: ImmunityBio, Inc.
- Current Assignee: ImmunityBio, Inc.
- Current Assignee Address: US CA Culver City
- Agency: Umberg Zipser LLP
- Agent Martin Fessenmaier
- The original application number of the division: US17056385
- Main IPC: C07K14/735
- IPC: C07K14/735 ; A61K38/17 ; C07K16/28 ; A61K39/395 ; C07K14/55 ; C07K14/54 ; C12N5/0783 ; A61P35/00 ; A61K35/17 ; A61K38/20 ; A61K45/06 ; C07K14/705 ; C07K16/32 ; A61K39/00

Abstract:
Recombinant NK cells, and especially recombinant NK-92 cells express a chimeric antigen receptor (CAR) having an intracellular domain of FcεRIγ. Notably, CAR constructs with an intracellular domain of FcεRIγ had a substantially prolonged duration of expression and significantly extended cytotoxicity over time. The CAR may be expressed from RNA and DNA, preferably as a tricistronic construct that further encodes CD16 and a cytokine to confer autocrine growth support. Advantageously, such constructs also enable high levels of transfection and expression of the recombinant proteins and provide a convenient selection marker to facilitate rapid production of recombinant NK/NK-92 cells.
Public/Granted literature
- US20210347850A1 FC-EPSILON CAR Public/Granted day:2021-11-11
Information query